Pharmaceuticals

Oramed Pharma

Oramed Pharma released FY2025 Q4 earnings on March 26 (EST), actual revenue USD 0, actual EPS USD 0.2319

Oramed Pharma released FY2025 earnings on March 26 (EST), actual revenue USD 2 M (forecast USD 2 M), actual EPS USD 1.5 (forecast USD 1.29)

Oramed Transfers Oral Drug Delivery Technology to Lifeward

Oramed Pharmaceuticals Reports Q3 2025 Earnings and Outlines Future Outlook

Oramed Pharma released FY2025 Q3 earnings on November 13 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD 1.13 (forecast USD -0.04)

Oramed Pharma released FY2025 9 Months Earnings on November 13 (EST), with actual revenue of USD 2M and EPS of USD 1.25

Oramed Pharma released FY2025 Semi-Annual Earnings on August 14 EST, with actual revenue of USD 2 M and EPS of USD 0.13

Oramed Pharma released FY2025 Q2 earnings on August 14 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD 0.31 (forecast USD -0.04)

Oramed Pharma released FY2025 Q1 earnings on May 15 (EST), actual revenue USD 2 M (forecast USD 0), actual EPS USD -0.19 (forecast USD -0.01)

Oramed Pharma released FY2024 annual earnings on March 27 (EST), actual revenue 0 USD (forecast 0 USD), actual EPS -0.4799 USD (forecast -0.24 USD)

Oramed Pharma released FY2024 Q4 earnings on March 27 (EST), actual revenue 0 USD (forecast 0 USD), actual EPS -0.2637 USD (forecast -0.02 USD)

Oramed Pharma released FY2024 Q3 earnings on November 7 (EST), actual revenue 0, actual EPS -0.4797 (forecast EPS 0.005)

Oramed Pharma released FY2024 9 Months Earnings on November 7, 2024 (EST) with actual revenue of USD 0 and EPS of USD -0.2223

Oramed Pharmaceuticals Inc reports higher quarterly adjusted earnings per share than last year

Oramed Pharma released FY2020 Q3 earnings on July 7, 2020 (EST), with actual revenue of 681K USD and EPS of -0.0983

InMed Pharmaceuticals

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Amesite

CN Energy

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

NextNRG

Meiwu Tech

Generation Income Properties

MetaVia

OceanPal

ORMP

Oramed Pharmaceuticals Inc. reported Q1 2026 results with $0 revenue and a net income of $38.31M, improving from a net loss of $(7.64) M in Q1 2025. Diluted EPS was $0.91, up from $(0.19) a year earlier. The company shifted to managing a medical technology portfolio, reduced R&D spending, and closed strategic transactions, including the Lifeward deal.

TradingView

iShares US Medical Devices

SPDR S&P Health Equip

Lifeward

Alpha Tau Medical

ALPHA TAU MEDICAL LTD C/WTS (TO PUR COM)

ORAMED PHARMACEUTICALS INC. 1Q 2026: Revenue $0 Net income $38.31M, EPS $0.91— 10-Q Summary

LFMD

CERS

The market has seen a 4.2% increase over the past week and a 29% rise over the last year, with earnings projected to grow by 16% annually. Oramed Pharmaceuticals, with a market cap of $142.78 million, has transitioned to profitability, reporting a net income of $64.05 million for 2025. Cerus Corporation, valued at $363.20 million, focuses on revenue growth in its Blood Safety segment, while LifeMD, with a market cap of $166.47 million, is advancing its telehealth services despite being unprofitable. Investors are encouraged to explore opportunities in penny stocks.

Simplywall

LifeMD

Cerus

iShares US Healthcare Providers

Health Care Select Sector SPDR

SPDR S&P Health

VG Health

Oramed Pharmaceuticals And Two Other Promising Penny Stocks For Savvy Investors

Oramed Pharmaceuticals reported $2.0 million in revenue for 2025, primarily from the HTIT license settlement, with a diluted EPS of $1.50. The company achieved a net income of $64.016 million due to significant non-operating revaluation gains, despite an operating loss of $15.088 million and minimal gross profit. Strategic shifts include transferring R&D responsibilities and entering joint activities to enhance operational focus and liquidity.

Oramed Pharmaceuticals 2025 10-K: $2.0M Revenue, $1.50 Diluted EPS

Earnings Watch

Oramed Pharma | 10-K: FY2025 Revenue: USD 2 M

LFWD

Lifeward Successfully Closes on Strategic Partnership with Oramed | LFWD Stock News

StockTitan

Lifeward Successfully Closes on Strategic Partnership with Oramed | LFWD Stock News

AIFF

In Monday's pre-market session, several health care stocks saw significant movement. Milestone Scientific (MLSS) shares surged 34.4% to $0.33, while BGM Group (BGM) rose 30.44% to $0.78. Zhengye Biotechnology (ZYBT) increased by 26.76% to $0.9, and Firefly Neuroscience (AIFF) gained 23.52% to $1.89. Apogee Therapeutics (APGE) and Insmed (INSM) also saw increases of 13.56% and 10.25%, respectively. Conversely, Valneva (VALN) dropped 36.8% to $6.52, followed by Impact BioMedical (IBO) down 23.04% to $0.6. Other notable losers included Onconetix (ONCO), Anika Therapeutics (ANIK), NeuroPace (NPCE), and CDT Equity (CDT).

benzinga_article

Invesco Dorsey Wright Healthcare Momentum ETF

VanEck Biotech ETF

Firefly Neuroscience

Milestone Scientific

Apogee Therapeutic

Proshares Ultra Nasdaq Biotech

Insmed

Zhengye Biotechnology

Invesco Biotechnology & Genome ETF

iShares Global Healthcare

Onconetix

First Trust NYSE Arca Biotech Index Fd

iShares US Pharma

12 Health Care Stocks Moving In Monday's Pre-Market Session

Lifeward Shareholders Approve Oratech Deal and Governance Changes

Tip Ranks

Lifeward Shareholders Approve Oratech Deal and Governance Changes

Oramed Pharmaceuticals (NASDAQ:ORMP) stock price surpassed its 50-day moving average of $3.26, reaching a high of $3.35 before closing at $3.31. The company has a market cap of $131.74 million and a PE ratio of 2.63. Analysts maintain a consensus "Hold" rating on the stock. Recently, Oramed announced a dividend of $0.25 per share, with a payout ratio of 19.84%. Institutional investors hold 12.73% of the stock, with notable increases in positions from several firms.

Market Beat

Oramed Pharmaceuticals (NASDAQ:ORMP) Stock Price Passes Above 50 Day Moving Average   - Here's Why

Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) experienced a 57.8% increase in short interest in January, totaling 644,912 shares as of January 30th. This represents approximately 2.0% of the company's stock sold short, with a short-interest ratio of 2.6 days based on an average daily trading volume of 246,539 shares. Institutional investors hold 12.73% of the stock, and the company recently declared a dividend of $0.25 per share. ORMP stock opened at $3.25, with a market cap of $129.35 million and a price-to-earnings ratio of 2.58.

Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) Short Interest Up 57.8% in January

Oramed Pharma(ORMP.US)

ORAMED PHARMACEUTICALS INC. 1Q 2026: Revenue $0 Net income $38.31M, EPS $0.91— 10-Q Summary

Oramed Pharmaceuticals And Two Other Promising Penny Stocks For Savvy Investors

Oramed Pharmaceuticals 2025 10-K: $2.0M Revenue, $1.50 Diluted EPS

Oramed Pharma | 10-K: FY2025 Revenue: USD 2 M

Lifeward Successfully Closes on Strategic Partnership with Oramed | LFWD Stock News

12 Health Care Stocks Moving In Monday's Pre-Market Session

Lifeward Shareholders Approve Oratech Deal and Governance Changes

Oramed Pharmaceuticals (NASDAQ:ORMP) Stock Price Passes Above 50 Day Moving Average - Here's Why

Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) Short Interest Up 57.8% in January